Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders

BACKGROUND: Immune checkpoint blockade (ICB) response in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) is limited to 15%–20% of patients and underpinnings of resistance remain undefined. METHODS: Starting with an anti-PD1 sensitive murine HNSCC cell line, we generated an isogeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Liye, Zeng, Zexian, Egloff, Ann Marie, Zhang, Fan, Guo, Fei, Campbell, Katie M, Du, Peter, Fu, Jingxin, Zolkind, Paul, Ma, Xiaojing, Zhang, Zhe, Zhang, Yi, Wang, Xiaoqing, Gu, Shengqing, Riley, Rachel, Nakahori, Yasutaka, Keegan, Joshua, Haddad, Robert, Schoenfeld, Jonathan D, Griffith, Obi, Manguso, Robert T, Lederer, James A, Liu, X Shirley, Uppaluri, Ravindra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772459/
https://www.ncbi.nlm.nih.gov/pubmed/35058328
http://dx.doi.org/10.1136/jitc-2021-004034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772459/
https://www.ncbi.nlm.nih.gov/pubmed/35058328
http://dx.doi.org/10.1136/jitc-2021-004034

Ejemplares similares